{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:40:12Z","timestamp":1789713612957,"version":"4.0.1"},"reference-count":87,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1097\/wnf.0b013e31825a68c5","type":"journal-article","created":{"date-parts":[[2012,7,17]],"date-time":"2012-07-17T14:54:40Z","timestamp":1342536880000},"page":"191-200","source":"Crossref","is-referenced-by-count":49,"title":["The Use of Aminopyridines in Neurological Disorders"],"prefix":"10.1097","volume":"35","author":[{"given":"Saam","family":"Sedehizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Keogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Maddison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210203","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1085\/jgp.68.5.519","article-title":". Dynamics of aminopyridine block of potassium channels in squid axon membrane.","volume":"68","author":"Yeh","year":"1976","journal-title":"J Gen Physiol"},{"key":"R2-7-20210203","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/274385a0","article-title":"Overcoming conduction failure in demyelinated nerve fibres by prolonging action potentials.","volume":"274","author":"Bostock","year":"1978","journal-title":"Nature"},{"key":"R3-7-20210203","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/mus.880030203","article-title":"Facilitatory effects of 4-aminopyridine on neuromuscular transmission in disease states.","volume":"3","author":"Kim","year":"1980","journal-title":"Muscle Nerve"},{"issue":"Pt 1","key":"R4-7-20210203","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/brain\/123.1.171","article-title":"Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension.","volume":"123","author":"Smith","year":"2000","journal-title":"Brain"},{"key":"R6-7-20210203","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/283570a0","article-title":"Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibers.","volume":"283","author":"Sherrat","year":"1980","journal-title":"Nature"},{"key":"R7-7-20210203","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mus.880030202","article-title":"Facilitatory effects of 4-aminopyridine on normal neuromuscular transmission.","volume":"3","author":"Kim","year":"1980","journal-title":"Muscle Nerve"},{"key":"R8-7-20210203","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1172\/JCI111331","article-title":". Effective treatment of verapamil intoxication with 4-aminopyridine in the cat.","volume":"73","author":"Agoston","year":"1984","journal-title":"J Clin Invest"},{"key":"R9-7-20210203","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/bja\/50.4.383","article-title":". Effects of 4-aminopyridine in Eaton Lambert Syndrome.","volume":"50","author":"Agoston","year":"1978","journal-title":"Br J Anaesth"},{"key":"R11-7-20210203","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/jnnp.54.12.1069","article-title":"3,4-diaminopyridine in the treatment of congenital (hereditary) myasthenia.","volume":"54","author":"Palace","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R12-7-20210203","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.410270215","article-title":"Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis.","volume":"27","author":"Davis","year":"1990","journal-title":"Ann Neurol"},{"key":"R13-7-20210203","first-page":"1293","article-title":". The safety and efficacy of 4-aminopyridine for motor weakness due to Guillain-Barre syndrome: a double-blind cross-over phase I drug trial.","volume":"81","author":"Meythaler","year":"2000","journal-title":"Arch Phys Med Rehabil"},{"key":"R14-7-20210203","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1056\/NEJM198404123101514","article-title":". Effects of 4-aminopyridine in elderly patients with Alzheimers disease.","volume":"310","author":"Wesseling","year":"1984","journal-title":"N Engl J Med"},{"issue":"3","key":"R18-7-20210203","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/jnnp.45.3.274","article-title":"Lack of effect of 4-aminopyridine on choreic movements.","volume":"45","author":"Lundh","year":"1982","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R19-7-20210203","first-page":"332","article-title":"Observations with 4-aminopyridine in Huntingtons chorea.","volume":"8","author":"Wesseling","year":"1980","journal-title":"IRCS Med Sci"},{"key":"R20-7-20210203","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","article-title":". 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.","volume":"321","author":"McEvoy","year":"1989","journal-title":"N Engl J Med"},{"key":"R21-7-20210203","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","article-title":". A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.","volume":"54","author":"Sanders","year":"2000","journal-title":"Neurology"},{"key":"R22-7-20210203","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","article-title":". Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, cross-over study.","volume":"86","author":"Wirtz","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R23-7-20210203","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/mus.21422","article-title":". 3,4-diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.","volume":"40","author":"Oh","year":"2009","journal-title":"Muscle Nerve"},{"key":"R25-7-20210203","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/135245850100700602","article-title":". Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine.","volume":"7","author":"Rossini","year":"2001","journal-title":"Mult Scler"},{"key":"R26-7-20210203","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.44.9.1701","article-title":". The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study.","volume":"44","author":"Smits","year":"1994","journal-title":"Neurology"},{"key":"R27-7-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ana.410320203","article-title":". The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study.","volume":"32","author":"van Diemen","year":"1992","journal-title":"Ann Neurol"},{"key":"R28-7-20210203","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1212\/WNL.48.4.817","article-title":". Quantitative assessment of sustained release 4-aminopyridine for symptomatic treatment of multiple sclerosis.","volume":"48","author":"Schwid","year":"1997","journal-title":"Neurology"},{"key":"R29-7-20210203","first-page":"A167","article-title":". Placebo-controlled double-blinded dose ranging study of fampridine-SR in multiple sclerosis.","volume":"60","author":"Goodman","year":"2003","journal-title":"Neurology"},{"key":"R30-7-20210203","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.wnl.0000326213.89576.0e","article-title":". Fampridine MS-F202 Study Group. Dose comparison trial of sustained-release fampridine in multiple sclerosis.","volume":"71","author":"Goodman","year":"2008","journal-title":"Neurology"},{"key":"R31-7-20210203","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":". Sustained-release oral fampridine in multiple sclerosis: a randomised, double blind, controlled trial.","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet"},{"key":"R32-7-20210203","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.22240","article-title":". A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.","volume":"68","author":"Goodman","year":"2010","journal-title":"Ann Neurol"},{"key":"R33-7-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/neu.1993.10.1","article-title":". 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients.","volume":"10","author":"Hansebout","year":"1993","journal-title":"J Neurotrauma"},{"key":"R34-7-20210203","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1592\/phco.19.9.713.31540","article-title":". Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial.","volume":"19","author":"Segal","year":"1999","journal-title":"Pharmacotherapy"},{"key":"R35-7-20210203","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1089\/089771501316919120","article-title":". Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury: a double-blinded, placebo-controlled crossover trial.","volume":"18","author":"Wolfe","year":"2001","journal-title":"J Neurotrauma"},{"key":"R36-7-20210203","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s004150170111","article-title":". Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury.","volume":"248","author":"van der Bruggen","year":"2001","journal-title":"J Neurol"},{"key":"R37-7-20210203","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1592\/phco.23.7.823.32731","article-title":". Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial.","volume":"23","author":"Grijalva","year":"2003","journal-title":"Pharmacotherapy"},{"key":"R38-7-20210203","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1592\/phco.23.2.133.32089","article-title":"Effects of 4-aminopyridine on cardiac repolarization, PR interval, and heart rate in patients with spinal cord injury.","volume":"23","author":"Wakana","year":"2003","journal-title":"Pharmacotherapy"},{"key":"R39-7-20210203","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1089\/neu.1998.15.837","article-title":". Randomized double-blind crossover trial of fampridine-SR (sustained-release 4-aminopyridine) in patients with incomplete spinal cord injury.","volume":"10","author":"Potter","year":"1998","journal-title":"J Neurotrauma"},{"key":"R40-7-20210203","first-page":"S1","article-title":". Double-blind, placebo-controlled, dose-escalating study evaluating the safety and efficacy of oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury.","volume":"25","author":"Ditunno","year":"2002","journal-title":"J Spinal Cord Med"},{"key":"R41-7-20210203","first-page":"S5","article-title":"Safety and efficacy of oral fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic motor-incomplete spinal cord injury.","volume":"25","author":"Lammertse","year":"2002","journal-title":"J Spinal Cord Med"},{"key":"R43-7-20210203","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1212\/WNL.0b013e318225ab07","article-title":". A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.","volume":"77","author":"Strupp","year":"2011","journal-title":"Neurology"},{"key":"R44-7-20210203","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1212\/01.WNL.0000078893.41040.56","article-title":". Treatment of downbeat nystagmus with 3,4-diaminopyridine A placebo-controlled study.","volume":"61","author":"Strupp","year":"2003","journal-title":"Neurology"},{"key":"R46-7-20210203","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1093\/brain\/awm172","article-title":". 4-Aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus.","volume":"130","author":"Kalla","year":"2007","journal-title":"Brain"},{"key":"R47-7-20210203","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4065\/70.6.532","article-title":"Treatment of stable chronic demyelinating polyneuropathy with 3,4-Diaminopyridine.","volume":"70","author":"Russell","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"R49-7-20210203","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/088307389601100608","article-title":". 3,4-Diaminopyridine in childhood myasthenia: double blind, placebo controlled trial.","volume":"11","author":"Anlar","year":"1996","journal-title":"J Child Neurol"},{"key":"R50-7-20210203","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0022-510X(96)00012-3","article-title":". A double-blind placebo-controlled study of 3,4-diaminopyridine in amytrophic lateral sclerosis patients on a rehabilitation unit.","volume":"138","author":"Aisen","year":"1996","journal-title":"J Neurol Sci"},{"key":"R51-7-20210203","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/WNL.31.3.265","article-title":"Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission.","volume":"31","author":"Murray","year":"1981","journal-title":"Neurology"},{"key":"R52-7-20210203","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ana.410210113","article-title":". 4-Aminopyridine improves clinical signs in multiple sclerosis.","volume":"21","author":"Stefoski","year":"1987","journal-title":"Ann Neurol"},{"key":"R53-7-20210203","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/jnnp.40.11.1109","article-title":". a new drug tested in the treatment of Eaton-Lambert syndrome.","volume":"40","author":"Lundh","year":"1977","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R54-7-20210203","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/neu.1994.11.433","article-title":". 4-aminopyridine-sensitive neurologic deficits in patients with spinal cord injury.","volume":"11","author":"Hayes","year":"1994","journal-title":"J Neurotrauma"},{"key":"R56-7-20210203","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0022-510X(94)00225-D","article-title":". 3,4-Diaminpyridine as a treatment for amyotrophic lateral sclerosis.","volume":"129","author":"Aisen","year":"1995","journal-title":"J Neurol Sci"},{"key":"R57-7-20210203","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1196\/annals.1325.037","article-title":". Effect of 3,4-Diaminopyridine on the postural control in patients with downbeat nystagmus.","volume":"1039","author":"Sprenger","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"R58-7-20210203","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1007\/s00415-011-5987-z","article-title":". 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation.","volume":"258","author":"Schniepp","year":"2011","journal-title":"J Neurol"},{"key":"R59-7-20210203","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jns.2010.01.021","article-title":". The effect of 3,4-diaminopyridine on the patients with hereditary pure cerebellar ataxia.","volume":"292","author":"Tsunemi","year":"2010","journal-title":"J Neurol Sci"},{"key":"R60-7-20210203","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1212\/01.WNL.0000125691.74109.53","article-title":". Treatment of episodic ataxia type 2 with the potassium channel blocker 4 aminopyridine.","volume":"62","author":"Strupp","year":"2004","journal-title":"Neurology"},{"key":"R61-7-20210203","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/jnnp.2004.045716","article-title":". 4-aminopyridine restores visual ocular motor function in upbeat nystagmus.","volume":"76","author":"Glasauer","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R62-7-20210203","first-page":"267A","article-title":"3,4-Diamimopyridine in myasthenia gravis and Lambert-Eaton syndrome.","volume":"39","author":"Sanders","year":"1989","journal-title":"Neurology"},{"key":"R63-7-20210203","first-page":"612","article-title":"Defect of neuromuscular conduction associated with malignant neoplasms.","volume":"187","author":"Lambert","year":"1956","journal-title":"Am J Physiol"},{"key":"R64-7-20210203","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1749-6632.1971.tb30750.x","article-title":"Quantal components of end-plate potentials in the myasthenic syndrome.","volume":"183","author":"Lambert","year":"1971","journal-title":"Ann NY Acad Sci"},{"key":"R65-7-20210203","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","article-title":"The Lambert-Eaton myasthenic syndrome: a review of 50 cases.","volume":"111","author":"ONeill","year":"1988","journal-title":"Brain"},{"key":"R66-7-20210203","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/01.WNL.0000130254.27019.14","article-title":". The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands.","volume":"63","author":"Wirtz","year":"2004","journal-title":"Neurology"},{"key":"R68-7-20210203","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","article-title":". Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes.","volume":"332","author":"Lennon","year":"1995","journal-title":"N Engl J Med"},{"key":"R69-7-20210203","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/jnnp.58.1.85","article-title":". An improved diagnostic assay for Lambert-Eaton myasthenic syndrome.","volume":"58","author":"Motomura","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R70-7-20210203","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0006-8993(78)90409-2","article-title":"Effects of 4-aminopyridine on neuromuscular transmission.","volume":"153","author":"Lundh","year":"1978","journal-title":"Brain Res"},{"issue":"2","key":"R73-7-20210203","first-page":"CD003279","article-title":"Treatment for Lambert-Eaton myasthenic syndrome 2010.","author":"Keogh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"R74-7-20210203","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/15563659509017992","article-title":". Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome.","volume":"33","author":"Boerma","year":"1995","journal-title":"J Toxicol Clin Toxicol"},{"key":"R75-7-20210203","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1136\/bmj.c6459","article-title":"What makes an orphan drug","volume":"341","author":"Hawkes","year":"2010","journal-title":"BMJ"},{"key":"R76-7-20210203","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/bmj.c6456","article-title":"The problem of orphan drugs.","volume":"341","author":"Ferner","year":"2010","journal-title":"BMJ"},{"key":"R77-7-20210203","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":". Reliability testing of the quantitative myasthenia gravis score.","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann NY Acad Sci"},{"key":"R79-7-20210203","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev.iy.10.040192.001101","article-title":"Immunological aspects of demyelinating diseases.","volume":"10","author":"Martin","year":"1992","journal-title":"Annu Rev Immunol"},{"key":"R80-7-20210203","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJM198206243062505","article-title":"Membranes, myelin, and the pathophysiology of multiple sclerosis.","volume":"306","author":"Waxman","year":"1982","journal-title":"N Engl J Med"},{"issue":"4","key":"R85-7-20210203","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1527-3458.2004.tb00029.x","article-title":"The use of 4-aminopyridine (fampridine) in demyelinating disorders.","volume":"10","author":"Hayes","year":"2004","journal-title":"CNS Drug Rev"},{"key":"R86-7-20210203","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/ana.410220417","article-title":". Central motor conduction in motor neuron disease.","volume":"22","author":"Hugon","year":"1987","journal-title":"Ann Neurol"},{"key":"R87-7-20210203","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CND.0b013e3182095b2b","article-title":". Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases.","volume":"12","author":"Bertorini","year":"2011","journal-title":"J Clin Neuromusc Dis"},{"key":"R88-7-20210203","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/ana.410160614","article-title":". Alexanders law: its behavior and origin in the human vestibulo-ocular reflex.","volume":"16","author":"Robinson","year":"1984","journal-title":"Ann Neurol"},{"key":"R90-7-20210203","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s002210100788","article-title":"Highly 4-aminopyridine sensitive delayed rectifier current modulates the excitability of guinea pig cerebellar Purkinje cells.","volume":"139","author":"Etzion","year":"2001","journal-title":"Exp Brain Res"},{"key":"R91-7-20210203","doi-asserted-by":"crossref","first-page":"7258","DOI":"10.1523\/JNEUROSCI.3582-09.2010","article-title":"The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.","volume":"30","author":"Alvina","year":"2010","journal-title":"J Neurosci"},{"key":"R92-7-20210203","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.pharmthera.2005.10.006","article-title":"Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment.","volume":"111","author":"Judge","year":"2006","journal-title":"Pharmacol Ther"},{"key":"R93-7-20210203","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0091270003251388","article-title":". Pharmacokinetics of an immediate-release oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury.","volume":"43","author":"Hayes","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"R95-7-20210203","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1212\/01.WNL.0000101675.61074.50","article-title":"Clinical spectrum of episodic ataxia type 2.","volume":"62","author":"Jen","year":"2004","journal-title":"Neurology"},{"key":"R96-7-20210203","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1093\/hmg\/6.11.1973","article-title":". Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p.","volume":"6","author":"Jodice","year":"1997","journal-title":"Hum Mol Genet"},{"key":"R97-7-20210203","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/brain\/awf130","article-title":"The neuronal channelopathies.","volume":"125","author":"Kullmann","year":"2002","journal-title":"Brain"},{"key":"R98-7-20210203","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410370302","article-title":"Episodic ataxias as channelopathies.","volume":"37","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"key":"R99-7-20210203","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1093\/brain\/awm126","article-title":". Primary episodic ataxias: diagnosis, pathogenesis and treatment.","volume":"130","author":"Jen","year":"2007","journal-title":"Brain"},{"key":"R100-7-20210203","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1212\/WNL.54.4.14A","article-title":"The pathophysiology of essential tremor.","volume":"54","author":"Deuschl","year":"2000","journal-title":"Neurology"},{"key":"R101-7-20210203","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.44.6.1054","article-title":". The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized placebo-controlled, double-blind, concentration controlled crossover trial.","volume":"44","author":"Bever","year":"1994","journal-title":"Neurology"},{"key":"R102-7-20210203","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00002826-199306000-00002","article-title":". M. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related efficacy and safety.","volume":"16","author":"VanDiemen","year":"1993","journal-title":"Clin Neuropharmacol"},{"key":"R103-7-20210203","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1212\/WNL.48.4.817","article-title":". Quantitative assessment of sustained release 4-aminopyridine for symptomatic treatment of multiple sclerosis.","volume":"48","author":"Schwid","year":"1997","journal-title":"Neurology"},{"key":"R104-7-20210203","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/15563659409011063","article-title":"Characterization of 4-aminopyridine in overdose.","volume":"32","author":"Stork","year":"1994","journal-title":"J Toxicol Clin Toxicol"},{"key":"R105-7-20210203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0014-2999(80)90378-7","article-title":"Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes.","volume":"61","author":"Molgo","year":"1980","journal-title":"Eur J Pharmacol"},{"key":"R106-7-20210203","first-page":"345","article-title":". Comparison of acute toxicity of some aminopyridines in vivo (mice) and in vitro (tissue culture) Toxicite aigue composaree de quelques aminopyridines in vivo (souris) et in vitro (cultures cellulaires).","volume":"26","author":"Lechat","year":"1968","journal-title":"Ann Pharm Fr"},{"key":"R110-7-20210203","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0404.1993.tb04205.x","article-title":". Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.","volume":"88","author":"Lundh","year":"1993","journal-title":"Acta Neurol Scand"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0b013e31825a68c5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:15:00Z","timestamp":1620976500000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201207000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e31825a68c5","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}